A randomized, double-blind study to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VL-2397 administered by infusion in healthy volunteers for treatment of fungal infections

Trial Profile

A randomized, double-blind study to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VL-2397 administered by infusion in healthy volunteers for treatment of fungal infections

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs VL 2397 (Primary)
  • Indications Aspergillosis; Mycoses
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 05 Jun 2017 Results published in a Vical media release.
    • 05 Jun 2017 According to a Vical media release, results from this trial were presented at the American Society of Microbiology (ASM) Microbe 2017 meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top